These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 23953051)

  • 21. Current perspective on the use of calcium channel blockers to treat hypertensive patients: the role of lercanidipine.
    Mancia G; Tsioufis K
    Future Cardiol; 2019 Jul; 15(4):259-266. PubMed ID: 31180724
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Barnidipine or Lercanidipine on Echocardiographic Parameters in Hypertensive, Type 2 Diabetics with Left Ventricular Hypertrophy: A Randomized Clinical Trial.
    Derosa G; Mugellini A; Querci F; Franzetti I; Pesce RM; D'Angelo A; Maffioli P
    Sci Rep; 2015 Aug; 5():12603. PubMed ID: 26243165
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New Insights into the Nephroprotective Potential of Lercanidipine.
    Hajdys J; Fularski P; Leszto K; Majchrowicz G; Stabrawa M; Młynarska E; Rysz J; Franczyk B
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762350
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Molecular effects of new calcium antagonists: is the principle of parcimony out of place?].
    Richard S; Virsolvy A; Fort A
    Ann Cardiol Angeiol (Paris); 2008 Jun; 57(3):166-73. PubMed ID: 18565491
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Hypertensive patients can benefit from a new generation of calcium channel blockers. Lercanidipine: effective with few side effects].
    Borghi C
    Rev Med Suisse; 2006 May; 2(65):1266-7. PubMed ID: 16767882
    [No Abstract]   [Full Text] [Related]  

  • 26. [The role of new dihydropyridine calcium channel blockers in the treatment of hypertension].
    Coca A
    An Med Interna; 2003 Jun; 20(6):279-81. PubMed ID: 12848596
    [No Abstract]   [Full Text] [Related]  

  • 27. Lercanidipine and T-type calcium current.
    Cerbai E; Mugelli A
    Eur Rev Med Pharmacol Sci; 2018 Jun; 22(12):4025-4031. PubMed ID: 29949180
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lercanidipine: short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic properties.
    Herbette LG; Vecchiarelli M; Sartani A; Leonardi A
    Blood Press Suppl; 1998; 2():10-7. PubMed ID: 9850437
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison between the antiproteinuric effects of the calcium channel blockers benidipine and cilnidipine in combination with angiotensin receptor blockers in hypertensive patients with chronic kidney disease.
    Abe M; Okada K; Maruyama N; Matsumoto S; Maruyama T; Fujita T; Matsumoto K; Soma M
    Expert Opin Investig Drugs; 2010 Sep; 19(9):1027-37. PubMed ID: 20649501
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine.
    Guarneri L; Angelico P; Ibba M; Poggesi E; Taddei C; Leonardi A; Testa R
    Arzneimittelforschung; 1996 Jan; 46(1):15-24. PubMed ID: 8821512
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cellular and molecular mechanisms of tissue protection by lipophilic calcium channel blockers.
    Menne J; Park JK; Agrawal R; Lindschau C; Kielstein JT; Kirsch T; Marx A; Muller D; Bahlmann FH; Meier M; Bode-Böger SM; Haller H; Fliser D
    FASEB J; 2006 May; 20(7):994-6. PubMed ID: 16597674
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lercanidipine: a novel dihydropyridine calcium-channel blocker.
    Epstein M
    Heart Dis; 2001; 3(6):398-407. PubMed ID: 11975824
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The effect of calcium channel blocker lercanidipine on lowgrade inflammation parameters in essential hypertension patients].
    Shurtz-Swirski R; Farah R; Sela S; Shapiro G; Klempef R; Snitkovski T; Kristal B
    Harefuah; 2006 Dec; 145(12):895-9, 942. PubMed ID: 17220028
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination therapy with lercanidipine and enalapril in the management of the hypertensive patient: an update of the evidence.
    Antza C; Stabouli S; Kotsis V
    Vasc Health Risk Manag; 2016; 12():443-451. PubMed ID: 27895487
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the cardioprotective and renoprotective effects of the L/N-type calcium channel blocker, cilnidipine, in adriamycin-treated spontaneously-hypertensive rats.
    Aritomi S; Harada E; Sugino K; Nishimura M; Nakamura T; Takahara A
    Clin Exp Pharmacol Physiol; 2015 Apr; 42(4):344-52. PubMed ID: 25582553
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antihypertensive effects of lercanidipine in experimental hypertensive rats and dogs.
    Sironi G; Montagna E; Greto L; Bianchi G; Leonardi A; Testa R
    Arzneimittelforschung; 1996 Feb; 46(2):145-52. PubMed ID: 8720303
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of dihydropyridinic calcium channel blockers in the management of hypertension.
    Coca A; Mazón P; Aranda P; Redón J; Divisón JA; Martínez J; Calvo C; Galcerán JM; Barrios V; Roca-Cusachs I Coll A
    Expert Rev Cardiovasc Ther; 2013 Jan; 11(1):91-105. PubMed ID: 23259449
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and tolerability of lercanidipine in mild to moderate hypertension among Asians of different ethnic groups.
    Chia YC; Yeoh ES; Ng CJ; Khoo EM; Chua CT
    Singapore Med J; 2009 May; 50(5):500-5. PubMed ID: 19495520
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of the fixed-dose combination lercanidipine-enalapril in renal protection.
    Egan CG; Pontremoli R
    J Nephrol; 2011; 24(4):428-37. PubMed ID: 21279953
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The pharmacological properties of lipophilic calcium antagonists.
    van Zwieten PA
    Blood Press Suppl; 1998; 2():5-9. PubMed ID: 9850436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.